UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000037835
Receipt number R000043137
Scientific Title The effect of HBF2019-02 on lipid metabolism
Date of disclosure of the study information 2019/09/16
Last modified on 2020/12/17 15:23:24

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

The effect of HBF2019-02 on lipid metabolism

Acronym

The effect of HBF2019-02 on lipid metabolism

Scientific Title

The effect of HBF2019-02 on lipid metabolism

Scientific Title:Acronym

The effect of HBF2019-02 on lipid metabolism

Region

Japan


Condition

Condition

Healthy adult

Classification by specialty

Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To investigate the effect of HBF2019-02 on lipid metabolism

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Lipid metabolism related indicators

Key secondary outcomes

Physical examination, and medical examination by hematology, blood biochemistry, urinalysis


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Double blind -all involved are blinded

Control

Placebo

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Food

Interventions/Control_1

Ingestion of test food for 12 weeks

Interventions/Control_2

Ingestion of placebo food for 12 weeks

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

65 years-old >

Gender

Male

Key inclusion criteria

(1) Healthy adult men
(2) LDL-Cho from 120 to 139 mg / dL or LDL-Cho from 140 to 159 mg / dL
(3) Subjects who can make self-judgment and are voluntarily giving written informed consent.

Key exclusion criteria

(1) Subjects with hepatic, renal, cardiac and/or organ disorders, diabetes, and/or other serious diseases.
(2) Subjects with abnormal liver and kidney function test values.
(3) Subjects with a disease currently being treated.
(4) Subjects with food and drug allergies.
(5) Subjects with anemia.
(6) Subjects who play intense sports and subjects who are on a diet.
(7) Subjects who cannot refrain from taking health foods (including certain health foods and functionally labeled foods) and designated quasi drugs during the test period.
(8) Those who continue to take medicines (including OTC and prescription drugs).
(9) Those who consume excessive alcohol, or who cannot ban alcohol from the day before the test to the day.
(10) Participants in or planning to participate in other clinical studies at the start of this study.
(11) Subjects who judged as unsuitable for this study by the principal investigator for any reasons.

Target sample size

22


Research contact person

Name of lead principal investigator

1st name Naoki
Middle name
Last name Miura

Organization

Miura Clinic, Medical Corporation Kanonkai

Division name

Internal Medicine

Zip code

530-0044

Address

Higashitenma building 9F, 1-7-17, Higashitenma, Kita-ku, Osaka, Osaka

TEL

06-6135-5200

Email

info@miula-cl.jp


Public contact

Name of contact person

1st name Chiyo
Middle name
Last name Yoshizane

Organization

Hayashibara CO., LTD.

Division name

R&D Division, Development Unit

Zip code

702-8006

Address

675-1, Fujisaki, Naka-ku, Okayama

TEL

086-276-3141

Homepage URL


Email

chiyo.yoshizane@hb.nagase.co.jp


Sponsor or person

Institute

Oneness Support Co., Ltd

Institute

Department

Personal name



Funding Source

Organization

Hayashibara CO., LTD

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

The Ethics Committee of Miura Clinic, Medical Corporation Kanonkai

Address

Higashitenma building 9F, 1-7-17, Higashitenma, Kita-ku, Osaka, Osaka

Tel

06-6135-5200

Email

mterashima@miura-cl.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

医療法人花音会みうらクリニック(大阪府) / Miura Clinic, Medical Corporation Kanonkai (Osaka)


Other administrative information

Date of disclosure of the study information

2019 Year 09 Month 16 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2019 Year 08 Month 22 Day

Date of IRB

2019 Year 08 Month 22 Day

Anticipated trial start date

2019 Year 09 Month 17 Day

Last follow-up date

2019 Year 12 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2019 Year 08 Month 28 Day

Last modified on

2020 Year 12 Month 17 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000043137


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name